Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583947 | 0.86 | CNR1 (0.45) | CNR1CNR2SCN9AEGFRERBB3 | |
| SCHEMBL3575055 | 0.83 | HTT (0.44) | CNR1CNR2EGFRMAPTRAB9A | |
| SCHEMBL3577056 | 0.80 | CNR1 (0.45) | CNR1CNR2SCN9AEGFRERBB3 | |
| SCHEMBL3577903 | 0.74 | NOTUM (0.49) | CNR1CNR2SCN9AEGFRERBB3 | |
| SCHEMBL15754423 | 0.71 | RPA1 (0.50) | LMNAMAPTRAB9AMEN1KMT2A | |
| SCHEMBL25310959 | 0.69 | RAB9A (0.64) | LMNAMAPTCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL29466342 | 0.69 | RAB9A (0.64) | LMNAMAPTCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL15760333 | 0.69 | MAPT (0.47) | CNR1CNR2LMNAMAPTRAB9A | |
| SCHEMBL3579788 | 0.68 | SCN9A (0.42) | CNR1CNR2SCN9AEGFRERBB3 | |
| SCHEMBL31587999 | 0.67 | POLB (0.58) | LMNAMEN1KMT2AKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | claimed |
| EP-2114916-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-11-11 | — | — | EP | claimed |
| WO-2008092942-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-08-07 | — | — | WO | claimed |
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | disclosed |
| EP-2114916-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008092942-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNA3, KCNQ1 | CNR1 608/4885CNR2 470/4885SCN9A 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.